Menu
1 min read · estimated
APPROVED USE
What FDA approved
Patients with metastatic castration-resistant prostate cancer associated with a deleterious germline or somatic BRCA mutation after androgen receptor-directed therapy and taxane chemotherapy.
LAMPGEN ANALYSIS
Why it matters
Made a PARP inhibitor available in a post-taxane BRCA-defined prostate cancer population under accelerated approval.
What research teams should watch
Capture the source of the BRCA result and both prior therapy classes when confirming eligibility.
PRIMARY RECORDS